Compositions and methods for treating hepatic fibrosis

A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an effective amount of exosomes isolated from a body fluid of a non-diseased subject, wherein the microRNA (miR) profile of the exosomes comprises one or both of:

• lack of up-regulation of one or both of the markers miR-26b and/or -122, as compared to the miR profile of a subject that is suffering from a fibrotic or hepatic disease or an associated disorder and/or lack of down-regulation of one or both of miR-9 and/or -196b as compared to the miR profile of a subject that is suffering from a fibrotic or hepatic disease or an associated disorder.

A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an effective amount of exosomes isolated from a body fluid of a non-diseased subject, wherein the microRNA (miR) profile of the exosomes comprises lack of up -regulation of miR-26b and -122, and lack of down-regulation of miR-9, and -196b, as compared to the miR profile of a subject that is suffering from a fibrotic or hepatic disease or an associated disorder.

A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an effective amount of exosomes isolated from a body fluid of a non-diseased subject, wherein the microRNA (miR) profile of the exosomes comprises lack of up-regulation or high expression of one or more, two or more, three or more, five or more, six or more, seven or more, eight or more, nine or more, ten or more, eleven or more, twelve or more, thirteen or more, fourteen or more, fifteen or more, or sixteen or more, or seventeen or more, or eighteen or more, or all of -7a, -26b, -122, -1906, -21, -22, -24, -34a, -155, -195, -677, -541, -125b, -500, -466j, -544, -1a-2, -1194, and/or -700 and/or lack of down-regulation or low expression of one or more, two or more, three or more, five or more, six or more, seven or more, eight or more, nine or more, ten or more, eleven or more, twelve or more, thirteen or more, fourteen or more, or fifteen or more, or all of miR-27a, -192, -214, -377, -196b, -9, -455, -23b, -106a, -200b, -532, -34c, -151, -653, -687, and/or -483, as compared to the miR profile of a subject that is suffering from a fibrotic or hepatic disease or an associated disorder.

A pharmaceutical composition comprising one or more, two or more, three or more, four or more, five or more, six or more, seven or more, eight or more, nine or more, ten or more, eleven or more, twelve or more, thirteen or more, fourteen or more, fifteen or more, or alternatively all of miR-9, -196b, -27a, -192, -214, -377, -455, -23b, -106a, -200b, -532, -34c, -151, -653, -687, and/or -483 and a pharmaceutically acceptable carrier.

A purified or isolated population of exosomes isolated from a body fluid of a non-diseased subject.

A purified or isolated population of exosomes isolated from a body fluid of a non-diseased subject, wherein the microRNA (miR) profile of the exosomes comprises lack up-regulation of one or both of the exosome markers miR-26b and/or -122, as compared to the exosome miR profile of a subject that is suffering from a liver or fibrotic disease or an associated disorder and/or comprise lack of down-regulation of one or both of miR-9 and/or -196b, as compared to the exosome miR profile of a subject that is suffering from a liver or fibrotic disease or an associated disorder.

A purified or isolated population of exosomes isolated from a body fluid of a non-diseased subject, wherein the microRNA (miR) profile of the exosomes comprises lack of up-regulation of one or both of miR-26b or -122 or lack of down-regulation of miR-9, or -196b, as compared to the exosome miR profile of a subject that is suffering from a liver or fibrotic disease or an associated disorder.